Biomark Diagnostics Inc.

C$0.45As of Sun 8 Nov 2026, 12:00 UTC

CSE:BUXHealthcare

Country Canada

PE (Fwd) —

TSR 10Y CAGR 20.41%

Div yield —

ROE (249.56%)

Diagnostics & Research

Beta (5Y) (0.38)

PE TTM —

TSR TTM 32.35%

Mkt cap C$47.92M

ROIC (128.81%)

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

$0.485

—

7.80%

—

TTM

FYE 31 Mar CAD

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

0.028

Revenue$M

—

0.153

0.163

0.154

0.060

0.029

(26.97%)

—

Revenue growth%

—

6.34

(5.52)

(61.23)

(50.78)

(5.52)

—

Gross margin%

—

100.00

—

(5154.95)

Operating margin%

—

(1128.45)

(806.71)

(1237.31)

(2436.77)

(100.00)

(1182.88)

—

(5127.11)

Net margin%

—

(1200.21)

(874.52)

(1249.73)

(2470.76)

(100.00)

(1224.97)

—

P/E ratio (avg)x

—

EV/EBITx

—

(2.23)

FCF yield (avg)%

—

(4.96)

(4.20)

(5.01)

(2.66)

(0.06)

(4.58)

—

(3833.67)

FCF margin%

—

(599.20)

(604.65)

(711.12)

(1828.20)

(100.00)

(657.89)

—

0.748

FCF / Net incomex

—

0.499

0.691

0.569

0.740

—

0.630

—

(128.81)

ROIC%

—

(1940.29)

(2.64)

(1940.29)

—

(249.56)

Return on equity%

—

(340.71)

(142.59)

(5.25)

(241.65)

—

(65.79)

Return on assets%

—

(251.57)

(131.08)

(61.49)

(79.40)

(1.37)

(105.24)

—

(0.01)

EPS$

—

(0.02)

(0.01)

—

EPS growth%

—

24.75

(26.58)

33.68

98.01

24.75

—

0.01

Bookvalue per sh$

—

(0.01)

0.02

—

0.01

(83.55%)

—

(0.01)

FCF per share$

—

(0.01)

—

Dividend per sh$

—

Div yield (avg)%

—

Payout ratio%

—

106.5

Shares (diluted)M

—

82.78

85.24

90.93

105.1

◌105.1

8.28%

—

Buyback yield%

—

(2.97)

(6.67)

(15.58)

◌—

(6.67)

—

2.226

D/E ratiox

—

(0.717)

(1.322)

0.261

2.189

2.315

(0.228)

—

48.57

Enterprise value$M

—

19.31

24.14

19.85

41.27

47.85

28.81%

—

LT debt$M

—

0.096

—

Peers (US$31.28M)

Cap (US$)

Spectral Medical Inc.

211.8M

—

Izotropic Corporation

5.887M

—

Leveljump Healthcare…

4.316M

—

Puriblood Medical Co.…

30.56M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(18.52)

(19.37)

Own earn%

—

Sh yield%

—

(6.67)

Owners

Insiders/Inst%

12.52

—

Short interest%

—

SBC / revenue%

139.06

Record

10Y

Profitable years

0/4

Revenue growth years

1/3

EPS growth years

2/3

Dividend streakyrs

Op margin range%

−2437–−807

$1 testx

—

Incr. ROIC%

—

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

$0.060M

(26.97%)

1.00×

Operating expenses

$1.517M

(7.00%)

2.07×

Asset mix

Trend

Other

66.73%

Cash and investments

33.27%

Reinvestment returns

No breakdown available